Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
This study has been completed.
Study NCT01096667   Information provided by Pfizer

First Received on March 26, 2010.   Last Updated on April 10, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes Mellitus, Type 2
Hypertension
Additional conditions recognized in this trial
Diabetes Mellitus
More general conditions related to this trial
Cardiovascular Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Vascular Diseases
Interventions listed in this trial
Placebo
1 mg PF-04971729
5 mg PF-04971729
25 mg PF-04971729
12.5mg HCTZ
Additional drug interventions recognized in this trial
Hydrochlorothiazide
More general drug interventions related to this trial
Antihypertensive Agents
Cardiovascular Agents
Diuretics
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services